
    
      Prospective, observational, un-blinded, multi-site study designed to collect data on patients
      implanted with a Model 106 VNS Therapy System from baseline through an EMU stay of up to 5
      days, and 6-month follow-up. After the 6-month follow-up, patients will continue follow-up
      for safety for approximately two years or until final regulatory approval of the product.
    
  